# Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

> **NCT03145038** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 30 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed
- **DRUG:** Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted
- **DRUG:** Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed
- **DRUG:** Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast
- **DRUG:** Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast
- **DRUG:** Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast

## Key facts

- **NCT ID:** NCT03145038
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-16
- **Primary completion:** 2017-08-29
- **Final completion:** 2017-10-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145038, "Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03145038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*